Bibliographic information

GuidelineWHO guidelines for malaria, 25 November 2022.
Year of Publication2022
Issuing InstitutionWorld Health Organization

Recommendation

Maintained

Treating cases of suspected severe malaria pending transfer to a higherlevel facility (pre-referral treatment): Where intramuscular injection of artesunate is not available, treat children < 6 years with a single rectal dose (10mg/kg bw) of artesunate, and refer immediately to an appropriate facility for further care. Do not use rectal artesunate in older children and adults.

Recommended in favor

Strong

Notes and Remarks

Practical Info Adjustment of parenteral dosing in renal failure of hepatic dysfunction The dosage of artemisinin derivatives does not have to be adjusted for patients with vital organ dysfunction. However, quinine accumulates in severe vital organ dysfunction. If a patient with severe malaria has persisting acute kidney injury or there is no clinical improvement by 48 h, the dose of quinine should be reduced by one third, to 10 mg salt/kg bw every 12 h. Dosage adjustments are not necessary if patients are receiving either haemodialysis or haemofiltration. Follow-on treatment The current recommendation of experts is to give parenteral antimalarial drugs for the treatment of severe malaria for a minimum of 24 h ounce started (irrespective of the patient’s ability to tolerate oral medication earlier) or until the patient can tolerate oral medication, before giving the oral follow-up treatment. After initial parenteral treatment, once the patient can tolerate oral therapy, it is essential to continue and complete treatment with an effective oral antimalarial drug by giving a full course of effective ACT (artesunate + amodiaquine, artemether + lumefantrine or dihydroartemisinin + piperaquine). If the patient presented initially with impaired consciousness, ACTs containing mefloquine should be avoided because of an increased incidence of neuropsychiatric complications. When an ACT is not available, artesunate + clindamycin, artesunate + doxycycline, quinine + clindamycin or quinine + doxycycline can be used for follow-on treatment. Doxycycline is preferred to other tetracyclines because it can be given once daily and does not accumulate in cases of renal failure, but it should not be given to children < 8 years or pregnant women. As treatment with doxycycline is begun only when the patient has recovered sufficiently, the 7-day doxycycline course finishes after the artesunate, artemether or quinine course. When available, clindamycin may be substituted in children and pregnant women. Continuing supportive care Patients with severe malaria require intensive nursing care, preferably in an intensive care unit where possible. Clinical observations should be made as frequently as possible and should include monitoring of vital signs, coma score and urine output. Blood glucose should be monitored every 4 h, if possible, particularly in unconscious patients. Please refer to Rectal artesunate for pre-referral treatment of severe malaria [236].

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

Guidelines for the treatment of malaria

Year2015
InstitutionWorld Health Organization
Guideline

WHO guidelines for malaria, 16 February 2021.

Year2021
InstitutionWHO
Guideline

WHO guidelines for malaria, 13 July 2021.

Year2021
InstitutionWHO
Guideline

WHO guidelines for malaria, 18 February 2022.

Year2022
InstitutionWHO
Guideline

WHO guidelines for malaria, 3 June 2022.

Year2022
InstitutionWHO
Guideline

WHO Guidelines for malaria, 14 March 2023

Year2023
InstitutionWHO